跳转至内容
Merck
CN
  • Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors.

Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors.

PloS one (2018-04-20)
Yugesh Kharel, Sayeh Agah, Tao Huang, Anna J Mendelson, Oluwafunmilayo T Eletu, Peter Barkey-Bircann, James Gesualdi, Jeffrey S Smith, Webster L Santos, Kevin R Lynch
摘要

Successful medicinal chemistry campaigns to discover and optimize sphingosine kinase inhibitors require a robust assay for screening chemical libraries and for determining rank order potencies. Existing assays for these enzymes are laborious, expensive and/or low throughput. The toxicity of excessive levels of phosphorylated sphingoid bases for the budding yeast, Saccharomyces cerevisiae, affords an assay wherein inhibitors added to the culture media rescue growth in a dose-dependent fashion. Herein, we describe our adaptation of a simple, inexpensive, and high throughput assay for assessing inhibitors of sphingosine kinase types 1 and 2 as well as ceramide kinase and for testing enzymatic activity of sphingosine kinase type 2 mutants. The assay was validated using recombinant enzymes and generally agrees with the rank order of potencies of existing inhibitors.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗-FLAG® M2-过氧化物酶(HRP) 小鼠抗, clone M2, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
SLM6031434 hydrochloride, ≥98% (HPLC)